比较了棘白菌素类药物（阿尼芬净）与其他 9 种抗真菌药物对念珠菌属、隐球菌属和曲霉菌属的体外抗菌活性：全球 SENTRY 抗菌药物监测计划（2008 年）的结果。
Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008).
机构信息
JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA.
出版信息
J Clin Microbiol. 2010 Aug;48(8):2984-7. doi: 10.1128/JCM.00328-10. Epub 2010 Jun 9.
Abstract
The SENTRY Antimicrobial Surveillance Program regularly monitors global susceptibility rates for a spectrum of both novel and established antifungal agents. Anidulafungin and the other echinocandins displayed sustained, excellent activity against Candida spp. and Aspergillus fumigatus, with >or=98% of MIC results at <or=2 microg/ml. Six yeast isolates (all Candida glabrata) showing caspofungin MIC values of >or=0.5 microg/ml were further analyzed for potential fks hot spot (HS) mutations; three isolates had confirmed mutations in the fks1 HS1 region (S645P), and three exhibited mutations in the fks2 HS1 region (S645F and S645P).
摘要
SENTRY 抗菌监测计划定期监测各种新型和已建立的抗真菌药物的全球敏感性率。阿尼达fungin 和其他棘白菌素对念珠菌属和烟曲霉表现出持续、优异的活性，MIC 结果<或=2μg/ml 时>或=98%。6 株酵母分离株（均为光滑念珠菌）的卡泊芬净 MIC 值>或=0.5μg/ml，进一步分析潜在的 fks 热点（HS）突变；3 株分离株在 fks1 HS1 区域（S645P）有确认的突变，3 株在 fks2 HS1 区域（S645F 和 S645P）有突变。
相似文献
1
Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008).比较了棘白菌素类药物（阿尼芬净）与其他 9 种抗真菌药物对念珠菌属、隐球菌属和曲霉菌属的体外抗菌活性：全球 SENTRY 抗菌药物监测计划（2008 年）的结果。
J Clin Microbiol. 2010 Aug;48(8):2984-7. doi: 10.1128/JCM.00328-10. Epub 2010 Jun 9.
2
Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains.全球范围内念珠菌菌株的 fks1 热点 1 突变低流行率。
Antimicrob Agents Chemother. 2010 Jun;54(6):2655-9. doi: 10.1128/AAC.01711-09. Epub 2010 Apr 5.
3
Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009).棘白菌素类和三唑类抗真菌药物对念珠菌属、新型隐球菌和烟曲霉的药敏谱：新 CLSI 临床折点和流行病学切点在 SENTRY 抗菌药物监测计划（2009 年）中用于耐药性特征分析的应用。
Diagn Microbiol Infect Dis. 2011 Jan;69(1):45-50. doi: 10.1016/j.diagmicrobio.2010.08.013.
4
Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018).长效棘白菌素类药物雷扎芬净与其他抗真菌药物对当代侵袭性真菌分离株的活性检测（SENTRY 项目，2016 年至 2018 年）。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.00099-20.
5
Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012).亚洲及西太平洋地区念珠菌、新型隐球菌和烟曲霉的抗真菌药敏性：哨兵抗真菌监测项目（2010 - 2012年）的数据
J Antibiot (Tokyo). 2015 Sep;68(9):556-61. doi: 10.1038/ja.2015.29. Epub 2015 Apr 22.
6
In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012.中国念珠菌属和曲霉属分离株对九种全身用抗真菌药物的体外抗真菌药敏试验：2010年至2012年哨兵抗真菌监测项目的数据
Mycoses. 2015 Apr;58(4):209-14. doi: 10.1111/myc.12299. Epub 2015 Feb 27.
7
Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.一种长效棘白菌素（CD101）及七种对照抗真菌药物在2014年哨兵抗真菌监测项目中针对全球当代侵袭性真菌分离株集合的活性测试。
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02045-16. Print 2017 Mar.
8
CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program.CD101，一种长效棘白菌素，与 SENTRY 2015 抗真菌监测计划中全球侵袭性真菌分离株的对照抗真菌药物进行了测试。
Int J Antimicrob Agents. 2017 Sep;50(3):352-358. doi: 10.1016/j.ijantimicag.2017.03.028. Epub 2017 Jul 6.
9
Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections.棘白菌素类和唑类药物对 2012 年全球侵袭性感染来源的酵母和霉菌的活性研究。
Int J Antimicrob Agents. 2014 Oct;44(4):320-6. doi: 10.1016/j.ijantimicag.2014.06.007. Epub 2014 Jul 23.
10
Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method.关于采用Etest琼脂扩散法检测念珠菌属和曲霉属对两性霉素B和棘白菌素耐药性的方法依赖性流行病学临界值的多中心研究。
Antimicrob Agents Chemother. 2016 Dec 27;61(1). doi: 10.1128/AAC.01792-16. Print 2017 Jan.
引用本文的文献
1
Emergence of Flucytosine-Resistant Candida tropicalis Clade, the Netherlands.荷兰出现对氟胞嘧啶耐药的热带假丝酵母菌进化枝。
Emerg Infect Dis. 2025 Jul;31(7):1354-1364. doi: 10.3201/eid3107.241918.
2
Wild-type MIC distributions and epidemiological cutoff values for 5-flucytosine and species as determined by EUCAST broth microdilution.通过欧洲抗菌药物敏感性试验委员会（EUCAST）肉汤微量稀释法测定的5-氟胞嘧啶的野生型最低抑菌浓度（MIC）分布及流行病学临界值和相关菌种。
JAC Antimicrob Resist. 2024 Oct 4;6(5):dlae153. doi: 10.1093/jacamr/dlae153. eCollection 2024 Oct.
3
Antibiotics, Analgesic Sedatives, and Antiseizure Medications Frequently Used in Critically Ill Neonates: A Narrative Review.危重新生儿常用抗生素、镇痛镇静药及抗惊厥药：一项叙述性综述
Children (Basel). 2024 Jul 18;11(7):871. doi: 10.3390/children11070871.
4
Synthesis and biological evaluation of aminothiazoles against Histoplasma capsulatum and Cryptococcus neoformans.合成及氨基噻唑类衍生物抗荚膜组织胞浆菌和新生隐球菌的生物评价。
Bioorg Med Chem. 2018 May 15;26(9):2251-2261. doi: 10.1016/j.bmc.2018.01.024. Epub 2018 Feb 2.
5
Design, synthesis, and biological evaluation of aminothiazole derivatives against the fungal pathogens Histoplasma capsulatum and Cryptococcus neoformans.抗真菌病原体荚膜组织胞浆菌和新型隐球菌的氨基噻唑衍生物的设计、合成及生物学评价
Bioorg Med Chem. 2015 Feb 1;23(3):532-47. doi: 10.1016/j.bmc.2014.12.006. Epub 2014 Dec 10.
6
Set of classical PCRs for detection of mutations in Candida glabrata FKS genes linked with echinocandin resistance.用于检测光滑念珠菌中与棘白菌素耐药性相关的FKS基因突变的一组经典聚合酶链反应。
J Clin Microbiol. 2014 Jul;52(7):2609-14. doi: 10.1128/JCM.01038-14. Epub 2014 May 14.
7
Identification of an aminothiazole with antifungal activity against intracellular Histoplasma capsulatum.鉴定一种具有抗细胞内荚膜组织胞浆菌活性的氨基噻唑。
Antimicrob Agents Chemother. 2013 Sep;57(9):4349-59. doi: 10.1128/AAC.00459-13. Epub 2013 Jul 1.
8
Antifungal susceptibility to amphotericin B, fluconazole, voriconazole, and flucytosine in Candida bloodstream isolates from 15 tertiary hospitals in Korea.韩国 15 家三级医院血源分离株念珠菌对两性霉素 B、氟康唑、伏立康唑和氟胞嘧啶的药敏性
Ann Lab Med. 2012 Nov;32(6):426-8. doi: 10.3343/alm.2012.32.6.426. Epub 2012 Oct 17.
9
Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance.Fks1 和 Fks2 在 Candida glabrata 中具有功能冗余性，但受到差异调节：对棘白菌素类耐药性的影响。
Antimicrob Agents Chemother. 2012 Dec;56(12):6304-9. doi: 10.1128/AAC.00813-12. Epub 2012 Oct 1.
10
The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.棘白菌素治疗失败的独立危险因素是侵袭性念珠菌病（由光滑念珠菌引起）患者存在 FKS 突变而不是 MIC。
Antimicrob Agents Chemother. 2012 Sep;56(9):4862-9. doi: 10.1128/AAC.00027-12. Epub 2012 Jul 2.
本文引用的文献
1
Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains.全球范围内念珠菌菌株的 fks1 热点 1 突变低流行率。
Antimicrob Agents Chemother. 2010 Jun;54(6):2655-9. doi: 10.1128/AAC.01711-09. Epub 2010 Apr 5.
2
Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media.棘白菌素类药物敏感性检测方法：比较 EUCAST EDef 7.1、CLSI M27-A3、Etest、纸片扩散法和琼脂稀释法与 RPMI 和 IsoSensitest 培养基的结果。
Antimicrob Agents Chemother. 2010 Jan;54(1):426-39. doi: 10.1128/AAC.01256-09. Epub 2009 Nov 2.
3
Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint.光滑念珠菌FKS1和FKS2突变对棘白菌素敏感性及1,3-β-D-葡聚糖合酶动力学的影响：对现有药敏折点的意义
Antimicrob Agents Chemother. 2009 Sep;53(9):3690-9. doi: 10.1128/AAC.00443-09. Epub 2009 Jun 22.
4
Consensus statement on the management of invasive candidiasis in Intensive Care Units in the Asia-Pacific Region.亚太地区重症监护病房侵袭性念珠菌病管理的共识声明。
Int J Antimicrob Agents. 2009 Sep;34(3):205-9. doi: 10.1016/j.ijantimicag.2009.03.014. Epub 2009 May 5.
5
Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007).当代抗真菌药物（包括新型棘白菌素阿尼芬净）对念珠菌属、隐球菌属和曲霉属的活性：哨兵抗菌监测计划（2006年至2007年）报告
J Clin Microbiol. 2009 Jun;47(6):1942-6. doi: 10.1128/JCM.02434-08. Epub 2009 Apr 22.
6
Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing.白色念珠菌、热带念珠菌和克鲁斯念珠菌中fks1基因的突变，与采用欧洲抗生素敏感性试验委员会的方法在AM3培养基中发现的卡泊芬净最低抑菌浓度升高相关。
Antimicrob Agents Chemother. 2008 Sep;52(9):3092-8. doi: 10.1128/AAC.00088-08. Epub 2008 Jun 30.
7
Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.针对念珠菌属对卡泊芬净、阿尼芬净和米卡芬净的药敏试验，其最低抑菌浓度（MIC）与结果的相关性：分析及MIC解释性折点建议
J Clin Microbiol. 2008 Aug;46(8):2620-9. doi: 10.1128/JCM.00566-08. Epub 2008 Jun 25.
8
Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds.针对阿尼芬净对霉菌药敏试验的CLSI肉汤微量稀释法（M38-A文件）的质量控制和参考指南。
J Clin Microbiol. 2007 Jul;45(7):2180-2. doi: 10.1128/JCM.00399-07. Epub 2007 May 2.
9
Acquired resistance to echinocandins in Candida albicans: case report and review.白色念珠菌对棘白菌素的获得性耐药：病例报告及文献复习
J Antimicrob Chemother. 2007 Jun;59(6):1076-83. doi: 10.1093/jac/dkm095. Epub 2007 Apr 27.
10
New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage.治疗真菌感染的新型药物：临床疗效与覆盖范围的差距
Clin Infect Dis. 2006 Oct 15;43(8):1060-8. doi: 10.1086/507891. Epub 2006 Sep 8.
Zotero 插件